Logo image of SLGL

SOL-GEL TECHNOLOGIES LTD (SLGL) Stock Fundamental Analysis

NASDAQ:SLGL - Nasdaq - IL0011417206 - Common Stock - Currency: USD

7.49  +0.2 (+2.76%)

After market: 7.05 -0.44 (-5.87%)

Fundamental Rating

3

SLGL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. SLGL has a great financial health rating, but its profitability evaluates not so good. SLGL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLGL has reported negative net income.
In the past year SLGL has reported a negative cash flow from operations.
In the past 5 years SLGL reported 4 times negative net income.
SLGL had a negative operating cash flow in each of the past 5 years.
SLGL Yearly Net Income VS EBIT VS OCF VS FCFSLGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

SLGL has a Return On Assets of -29.52%. This is comparable to the rest of the industry: SLGL outperforms 53.85% of its industry peers.
SLGL has a Return On Equity (-36.67%) which is in line with its industry peers.
Industry RankSector Rank
ROA -29.52%
ROE -36.67%
ROIC N/A
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
SLGL Yearly ROA, ROE, ROICSLGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

1.3 Margins

SLGL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLGL Yearly Profit, Operating, Gross MarginsSLGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

SLGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SLGL remains at a similar level compared to 1 year ago.
Compared to 5 years ago, SLGL has more shares outstanding
There is no outstanding debt for SLGL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLGL Yearly Shares OutstandingSLGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SLGL Yearly Total Debt VS Total AssetsSLGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -7.14, we must say that SLGL is in the distress zone and has some risk of bankruptcy.
SLGL has a worse Altman-Z score (-7.14) than 65.64% of its industry peers.
SLGL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.14
ROIC/WACCN/A
WACC9.07%
SLGL Yearly LT Debt VS Equity VS FCFSLGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 5.92 indicates that SLGL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.92, SLGL is in the better half of the industry, outperforming 76.41% of the companies in the same industry.
A Quick Ratio of 5.92 indicates that SLGL has no problem at all paying its short term obligations.
SLGL has a better Quick ratio (5.92) than 76.41% of its industry peers.
Industry RankSector Rank
Current Ratio 5.92
Quick Ratio 5.92
SLGL Yearly Current Assets VS Current LiabilitesSLGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

SLGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.90%, which is quite impressive.
Looking at the last year, SLGL shows a very strong growth in Revenue. The Revenue has grown by 605.30%.
The Revenue for SLGL have been decreasing by -12.81% on average. This is quite bad
EPS 1Y (TTM)42.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.29%
Revenue 1Y (TTM)605.3%
Revenue growth 3Y-28.28%
Revenue growth 5Y-12.81%
Sales Q2Q%121.24%

3.2 Future

SLGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.73% yearly.
The Revenue is expected to grow by 37.05% on average over the next years. This is a very strong growth
EPS Next Y-42.86%
EPS Next 2Y0%
EPS Next 3Y1.18%
EPS Next 5Y35.73%
Revenue Next Year-42.11%
Revenue Next 2Y-12.86%
Revenue Next 3Y8.74%
Revenue Next 5Y37.05%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SLGL Yearly Revenue VS EstimatesSLGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SLGL Yearly EPS VS EstimatesSLGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLGL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLGL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLGL Price Earnings VS Forward Price EarningsSLGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLGL Per share dataSLGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y1.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (6/25/2025, 8:11:05 PM)

After market: 7.05 -0.44 (-5.87%)

7.49

+0.2 (+2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-19 2025-05-19
Earnings (Next)08-14 2025-08-14
Inst Owners19.04%
Inst Owner Change1.42%
Ins Owners1.37%
Ins Owner ChangeN/A
Market Cap20.90M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.57%
Min Revenue beat(2)-86.37%
Max Revenue beat(2)95.51%
Revenue beat(4)2
Avg Revenue beat(4)87.42%
Min Revenue beat(4)-86.37%
Max Revenue beat(4)405.4%
Revenue beat(8)4
Avg Revenue beat(8)42.2%
Revenue beat(12)4
Avg Revenue beat(12)2.1%
Revenue beat(16)6
Avg Revenue beat(16)-4.56%
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.81
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-4.68
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-4.98
FCFYN/A
OCF(TTM)-4.98
OCFYN/A
SpS4.14
BVpS10.34
TBVpS10.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.52%
ROE -36.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.55%
ROA(5y)-33.3%
ROE(3y)-47.5%
ROE(5y)-38.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.86%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.92
Quick Ratio 5.92
Altman-Z -7.14
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)23.47%
Cap/Depr(5y)26.73%
Cap/Sales(3y)4.34%
Cap/Sales(5y)3.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-39.29%
EPS Next Y-42.86%
EPS Next 2Y0%
EPS Next 3Y1.18%
EPS Next 5Y35.73%
Revenue 1Y (TTM)605.3%
Revenue growth 3Y-28.28%
Revenue growth 5Y-12.81%
Sales Q2Q%121.24%
Revenue Next Year-42.11%
Revenue Next 2Y-12.86%
Revenue Next 3Y8.74%
Revenue Next 5Y37.05%
EBIT growth 1Y59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.66%
OCF growth 3YN/A
OCF growth 5YN/A